Respiratory Syncytial Virus (RSV) Vaccine

Respiratory Syncytial Virus (RSV) infection is caused by the respiratory syncytial virus (RSV). RSV is a common virus that primarily affects the respiratory system, particularly the lungs and airways. It is a leading cause of respiratory tract infections in infants, young children, and older adults. Common symptoms include coughing, sneezing, runny nose, sore throat and fever. In most cases, RSV infection causes mild, cold-like symptoms. However, in some individuals, particularly those with weakened immune systems or underlying health conditions, RSV infection can lead to more severe complications, such as bronchiolitis or pneumonia. Severe patients need hospitalisation for treatment.

• Adults aged 60 or above

• High-risk individuals with chronic conditions such as asthma, diabetes, or chronic obstructive pulmonary disease

• Pregnant women at 32-36 weeks of gestation, providing maternal immunization to protect infants from RSV infection for up to 6 months after birth (applicable to ABRYVSO only)

ABRYSVO and AREXVY RSV vaccines are both single-dose injection given in the upper arm.

ABRYSVO

AREXVY